K961256 · Beckman Instruments, Inc. · LEG · May 15, 1996 · Clinical Toxicology
Device Facts
Record ID
K961256
Device Name
SYNCHRON SYSTEMS VALPROIC ACID (VPA) REAGENT
Applicant
Beckman Instruments, Inc.
Product Code
LEG · Clinical Toxicology
Decision Date
May 15, 1996
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 862.3645
Device Class
Class 2
Intended Use
The SYNCHRON Systems Valproic Acid reagent in conjunction with the SYNCHRON Drug Calibrator 1 is intended for use in the quantitative determination of valproic acid in human serum and plasma. This assay is designed for use with the family of SYNCHRON System analyzers which include the SYNCHRON CX®4, CX®4CE, CX4 DELTA, CX5, CX5CE, CX5 DELTA, CX7, and CX7 DELTA Systems.
Device Story
The SYNCHRON Systems Valproic Acid (VPA) test system is an in vitro diagnostic reagent kit used with SYNCHRON clinical analyzers (CX4/CX5/CX7 series). It measures valproic acid concentrations in human serum or plasma samples. The system utilizes the SYNCHRON Drug Calibrator 1 for calibration. Operated by laboratory technicians in clinical settings, the device provides quantitative results to healthcare providers. These results assist in therapeutic drug monitoring, allowing clinicians to adjust valproic acid dosages to maintain therapeutic levels and optimize patient outcomes.
Clinical Evidence
Bench testing only. Precision studies (n=80 per level) demonstrated within-run imprecision (%CV) of 2.0-3.1% and total imprecision of 2.7-4.6% across low, mid, and high ranges. Method comparison against predicate (n=104) yielded r=0.9857. Analytical measuring range established at 10-150 μg/mL.
Technological Characteristics
In vitro diagnostic reagent system for quantitative immunoassay. Designed for use on Beckman SYNCHRON CX series clinical analyzers. Measuring range 10-150 μg/mL. Stability of 24 months for both reagent and calibrator.
Indications for Use
Indicated for the quantitative measurement of valproic acid in human serum and plasma for patients requiring therapeutic drug monitoring.
Regulatory Classification
Identification
A neuroleptic drugs radioceptor assay test system is a device intended to measure in serum or plasma the dopamine receptor blocking activity of neuroleptic drugs and their active metabolites. A neuroleptic drug has anti-psychotic action affecting principally psychomotor activity, is generally without hypnotic effects, and is a tranquilizer. Measurements obtained by this device are used to aid in determining whether a patient is taking the prescribed dosage level of such drugs.